On Friday, Oct. 1, 2021, drug manufacturer Merck and its partner Ridgeback Biotherapeutics announced an antiviral pill that could drastically reduce the severity of COVID-19 infections.
The drug, molnupiravir, was shown in clinical trials to reduce the risk of COVID-19 hospitalizations and death by around 50%. Merck said they will be seeking emergency use authorization (EUA) from the Food and Drug Administration as soon as possible.
“Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed.” Wendy Holman, Ridgeback Biotherapeutics CEO
For more information:
All COVID-19 Resources
EOB Featured Workshop
